Cardiff University | Prifysgol Caerdydd ORCA
Online Research @ Cardiff 
WelshClear Cookie - decide language by browser settings

Enteric‐release glyceryl trinitrate in active Crohn’s disease: a randomized, double‐blind, placebo‐controlled trial

Hawkes, N. D., Richardson, C., Ch'Ng, C. L., Green, J. T., Evans, B. K., Williams, J., Rhodes, P., Rhodes, J., Swift, G. L., Thomas, G. A. O., Hawthorne, A. B., Kingham, J. G. C. and Mayberry, J. F. 2001. Enteric‐release glyceryl trinitrate in active Crohn’s disease: a randomized, double‐blind, placebo‐controlled trial. Alimentary Pharmacology and Therapeutics 15 (12) , pp. 1867-1873. 10.1046/j.1365-2036.2001.01120.x

Full text not available from this repository.

Abstract

Background: Mucosal ischaemia may contribute to the pathogenesis of Crohn’s disease. Microvascular abnormalities have been found in colonic resection specimens, and mucosal levels of constitutive nitric oxide synthase are reduced. Aim: To assess the efficacy of a novel, enteric-release formulation of the nitric oxide donor, glyceryl trinitrate, aimed at increasing the mucosal circulation and relaxing smooth muscle in the affected bowel. Methods: The trial was randomized, double-blind and placebo-controlled. Baseline disease activity was assessed by a structured symptom diary, with blood tests and a quality of life assessment. Patients with a Crohn’s disease activity index of ≥ 150 and < 450 were randomized to receive 12 weeks of either glyceryl trinitrate (initially 6 mg twice daily, increasing to 9 mg twice daily after 6 weeks) or an identical placebo. Assessments were repeated at 6 and 12 weeks. Results: Seventy patients (22 male) entered the study; 34 were given glyceryl trinitrate and 36 placebo. At 12 weeks, there were no differences between the treatment groups in terms of Crohn’s disease activity index, pain, stool frequency, inflammatory markers or quality of life scores. Conclusions: Enteric-release glyceryl trinitrate did not benefit patients with mild to moderately active Crohn’s disease. Whilst ischaemia may contribute to the pathogenesis of Crohn’s disease, our results fail to provide supportive evidence for this hypothesis.

Item Type: Article
Date Type: Publication
Status: Published
Schools: Schools > Medicine
Publisher: Wiley
ISSN: 1365-2036
Last Modified: 07 Aug 2026 14:45
URI: https://orca.cardiff.ac.uk/id/eprint/188789

Actions (repository staff only)

Edit Item Edit Item